Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04226898 · ClinicalTrials.gov registry record · Phase 2
Synbiotic Compound to Reduce Symptoms of Schizophrenia
A Phase 2 study, sponsored by Sheppard Pratt Health System.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT04226898: Recruiting Phase 2 study, sponsored by Sheppard Pratt Health System.
NCT04226898 is a Phase 2 study that is actively recruiting participants, run by Sheppard Pratt Health System. The registered enrollment target is 68 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (49% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04226898, a Phase 2 study, is actively recruiting participants, sponsored by Sheppard Pratt Health System.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if taking a synbiotic supplement versus a placebo will reduce symptoms of schizophrenia when used in addition to standard antipsychotic medications.
Primary Outcome
The Positive and Negative Syndrome Scale (PANSS) measures psychiatric symptomatology, especially related to psychosis. The complete PANSS contains ratings for 30 symptoms, including 7 positive symptoms, 7 negative symptoms, and 16 general psychiatric symptoms. The severity of each symptom is rated on a scale ranging from 1 (minimal) to 7 (extreme); higher scores indicate increased symptomatology. Total PANSS scores include scores from all categories and range from 30 to 210 units on a scale.
Interventions
- BIOLOGICAL Synbiotic Supplement
- BIOLOGICAL Inert Compound
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2022-02-21 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT04226898 shows while recruiting
NCT04226898 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (49% lower).
The record links to 0 conditions, and to 2 interventions - of which Synbiotic Supplement is the first listed.
NCT04226898 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04226898 about?
NCT04226898 is a clinical study titled "Synbiotic Compound to Reduce Symptoms of Schizophrenia". The purpose of this study is to determine if taking a synbiotic supplement versus a placebo will reduce symptoms of schizophrenia when used in addition to standard antipsychotic medications.
What is the current status of trial NCT04226898?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2022-02-21. Estimated completion is 2027-12.
What interventions are being tested in trial NCT04226898?
The interventions under investigation include: Synbiotic Supplement (BIOLOGICAL), Inert Compound (BIOLOGICAL).
Who is sponsoring clinical trial NCT04226898?
This trial is sponsored by Sheppard Pratt Health System, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04226898's enrollment target sits among peer trials
68 967th of 2000 higher than 1,027 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI